It is a Phase II trial for recurrent endometrial or ovarian cancer with ANY “endometriod” histology including mixed or carcinosarcoma as long as a portion of it had “endometriod” histology. DKN-01 (an inhibitor of DKK1, which modulates both the canonical and noncanonical Wnt signaling pathway) +/- weekly Paclitaxel. DKK1 is thought to promote immune evasion, so blocking it activates the immune system to fight the cancer.
Here is the link for more information:
Dr. Rebecca Arend is the national Principle Investigator for the study. For further information or consultation to determination whether you meet the criteria to join the study you may contact Dr. Arend’s office at 205-996-4662.
Alternatively, you can go to providerdirectory.uabmedicine.org, type in Dr. Rebecca Arend’s name and fill out an appointment form on line.
Thanks,
The GCS Project Team
Our sister never–not for a minute–lost hope. March marks the third anniversary we remember our sister, Diane Redington, who lost her courageous three-year battle to gynecologic carcinosarcoma (GCS/MMMT) on March… Read More »
Dr. Arend, an assistant professor and senior scientist at the University of Alabama at Birmingham has received funding from 2 drug companies – Bristol Meyers Squib and Exelixis to perform… Read More »
